key: cord-0303461-satzzwd2 authors: Zhang, Jingning; Dutta, Diptavo; Köttgen, Anna; Tin, Adrienne; Schlosser, Pascal; Grams, Morgan E.; Harvey, Benjamin; Yu, Bing; Boerwinkle, Eric; Coresh, Josef; Chatterjee, Nilanjan title: Large Bi-Ethnic Study of Plasma Proteome Leads to Comprehensive Mapping of cis-pQTL and Models for Proteome-wide Association Studies date: 2021-10-06 journal: bioRxiv DOI: 10.1101/2021.03.15.435533 sha: e79bba2a50ea4731a0c06e661b20a789689feafd doc_id: 303461 cord_uid: satzzwd2 Improved understanding of genetic regulation of proteome can facilitate the identification of causal mechanisms for complex traits. We analyzed data on 4,657 plasma proteins from 7,213 European American (EA) and 1,871 African American individuals from the ARIC study, and further replicated findings on 467 AA individuals from the AASK study. We identified 2,004 plasma proteins in EA and 1,618 in AA, with majority overlapping, which showed significant genetic associations with common variants in cis-regions. Availability of AA sample led to smaller credible sets and identification of a significant number of population-specific cis-pQTLs. Estimates of cis-heritability for proteins were similar across EA and AA (median cis-h2=0.09 for EA and 0.10 for AA) and tended to be lower than those of gene expressions. Elastic-net-based algorithms produced high accuracy for protein prediction in each population, but models developed in AA were more transportable to EA than conversely. An illustrative application of proteome-wide association studies (PWAS) to serum urate and gout, implicated several proteins, including IL1RN, revealing the promise of the drug anakinra to treat acute gout flares. Our study demonstrates the value of large and diverse ancestry study for understanding genetic mechanisms of molecular phenotypes and their relationship with complex traits. Genome-wide association studies (GWAS) to date have cumulatively mapped tens of thousands 48 of loci containing common genetic variants associated with complex traits 1, 2 . As the majority of 49 the variants are in non-coding regions 3, 4 , researchers have focused on understanding the role of 50 gene-expression regulation as a mechanism for complex trait genetic association 5-9 . There is 51 known to be substantial overlap between genetic variations regulating gene expression and 52 those influencing complex traits 7-9 , but only a small fraction of GWAS heritability of complex 53 traits can be explained by mediating effects through bulk gene-expression 10, 11 . While it is likely 54 that future studies with more extensive cell-type specific gene expression measurements will 55 lead to additional insights, comprehensive understanding of causal mechanisms for complex 56 traits will ultimately require the integration of data from various types of genomic and molecular 57 traits 11 . Proteins, the ultimate product of the transcripts, are subject to post-translational 58 modifications and processing, and contain additional information that cannot be detected at the 59 level of the transcriptome. 60 61 3a) and similar patterns were also observed when in GTEx V8 (Supplementary Fig. 5) . The pattern 231 is expected given the closer relationship of genetic variation to transcripts than to the encoded 232 proteins, which are subject to additional processing including post-translational modifications. 233 234 Next, we built protein imputation models for cis-heritable SOMAmers using an elastic net 235 machine learning method with 5-fold cross-validation as has been used for modeling gene-236 expression 27 . The median accuracy for the elastic-net models for protein predictions, evaluated 237 as the prediction R 2 standardized by cis-heritability (R 2 /cis-h 2 ), was 0.79 and 0.69 for the EA and 238 AA populations, respectively. Compared with imputation models built only with the top cis-pQTL, 239 the elastic net models gained, 36% and 40% of accuracy for the EA and AA populations, 240 respectively ( Fig. 3b, Supplementary Table 13) . In cross-ethnic analysis, we found that models 241 trained in the EA population performed worse in the AA population than the converse, in spite 242 of a much smaller sample size in AA, again indicating the advantage of the latter population to 243 identify causal pQTLs which are more likely to have robust effects across ethnic groups (Fig. 3c) . 244 245 We then explored cis-regulated genetic correlation between plasma proteins and expression 248 levels for the underlying genes across a variety of tissues. We used genotype data for Europeans 249 from the Phase-3 1000 Genome Project (1000Genome) 51 to evaluate Pearson's correlation 250 coefficients between genotypically-imputed protein levels, and genotypically-imputed 251 expression levels, with the latter being computed based on models that have been previously 252 built and published by Gusev et al. 28 based on data from the GTEx (V7) consortium (Supplementary Tables 13 and 14) . We also used models based on GTEx (V8) developed by the 254 same group (available through personal communication), but because of their preliminarily 255 nature we present the all analyses involving imputed gene-expression using the V7 models and 256 present preliminary results from the V8 models as supplementary data. The analysis was 257 restricted to the European population due to the lack of gene-expression imputation models for 258 AA population. Overall, genetically imputed plasma proteins are only moderately correlated with 259 those for gene expression levels (Fig. 3d) . Consistent with previous studies 52 , we find that plasma 260 proteins show strongest genetic correlations with genes expression levels in the liver, the organ 261 responsible for the synthesis of many highly abundant plasma proteins. The lowest genetic 262 correlations were seen for brain-related tissues, which may be due to the blood-brain barrier. In 263 GTEx (V8), that included a larger number of overlapping genes with our SOMAmers, we observed 264 a similar pattern for high-/low-rank tissues for expression-protein genetic correlations although 265 the absolute levels of these correlations were bit lower (Supplementary correlations between direct plasma protein measurements and imputed gene expression levels 267 in ARIC showed similar trend but have generally much lower values as they account for additional 268 variability of protein measurements due to non-genetic factors (Supplementary Fig. 6) . 269 270 We illustrate an application of the protein imputation model by conducting proteome-wide 272 association studies for two related complex traits: (1) serum urate, a highly heritable biomarker 273 of health representing the end product of purine metabolism in humans, and (2) gout, a complex 274 disease caused by urate crystal deposition in the setting of elevated urate levels and the resulting 275 inflammatory response. We obtained GWAS summary-statistics data for these traits generated by the CKDGen Consortium 32 involving a total sample size of N=288,649 and N=754,056, 277 respectively. As this GWAS was conducted primarily in EA population, we carried out the PWAS 278 analysis using the model generated for the EA population. 279 280 We used a computational pipeline previously developed for conducting TWAS based on GWAS 281 summary-statistics 28, 53 to carry out an analogous PWAS analysis. Simulation studies showed that 282 type 1 error of PWAS analysis based on our protein imputation weights are well controlled 283 ( Supplementary Fig. 7) . Among SOMEmers that showed significant cis-heritability, we identified 284 10 and 4 distinct loci containing genes for which the encoded proteins or protein complexes were 285 found to be significantly (p-value < 3.7x10 -5 ) associated with serum urate and gout, respectively. 286 We further examined whether the PWAS signals could be explained by cis-genetic regulation of 287 the expression of nearby (1Mb region around) genes and vice versa by performing bivariate 288 analysis conditioning on imputed expression values for nearby genes that are found to be 289 significantly associated based on the TWAS analysis. Main results were based on GTEx V7 models 290 ( Fig. 4, Table 1 , Supplementary Fig. 8) , and further validated using GTEx V8 preliminary models 291 (Supplementary Table 16 ). For the nearby TWAS analysis, we considered significance of genes 292 based on two trait-relevant tissues available in GTEx V7, namely whole blood and liver, but also 293 explored other tissues more broadly (see Methods). 294 The conditional PWAS analysis of serum urate revealed several interesting patterns (Table 1a) . 296 First, there were PWAS signals that could be largely explained by nearby TWAS signals for the 297 corresponding transcript in relevant tissues (e.g., INHBB in liver, and SNUPN in whole blood). This 298 may be indicative of genetic loci influencing serum urate through altered gene expression and 299 corresponding protein levels 54 . Second, there were also PWAS signals that could be largely 300 explained by the TWAS signal of the corresponding transcript in other tissues (e.g. B3GAT3 in 301 brain), but not in whole blood or liver. Such examples support the notion that the evaluation of 302 diverse potential tissues of action may be important to characterize these genetic loci. However, 303 the effects of TWAS of B3GAT3 in brain tissues are negative whereas the effect of its PWAS is 304 positive. We found the opposite direction is consistent with their negative genetic correlation 305 between plasma protein and gene-expression in those tissues. Future investigation for the 306 complicated directions of effects is worthwhile. Third, for the locus around INHBC, the plasma 307 PWAS signal for INHBC explains the most significant nearby TWAS signal R3HDM2 in thyroid 308 (conditional p-value of TWAS signal = 4.12x10 -1 ) but not vice versa (conditional p-value of PWAS 309 signal = 6.84x10 -34 ). We also found the top TWAS gene-tissue signals detected using the V7 310 models show similar level of significance, direction and magnitude of association when the 311 analyses were repeated using the V8 models and the corresponding conditional PWAS-TWAS 312 conditional analysis show qualitatively similar results (Supplementary there was strong genetic correlation between plasma protein and gene expression there was also 316 strong evidence of colocalization (e.g. INHBB in liver, and B3GAT3 in brain), which gives the most 317 confidence in those findings. 318 319 Finally, the PWAS of gout revealed a finding illustrating the potential to detect potential drug 320 targets for treating gout based on the significant association with the Interleukin 1 Receptor 321 Antagonist protein (IL1RN, p-value = 2.22x10 -5 ) ( Table 1b) . IL1RN binds to its target, the cell surface interleukin-1 receptor (IL1R1), thereby inhibiting the pro-inflammatory effect of 323 interleukin-1 signaling. Anakinra, an anti-inflammatory drug approved to treat rheumatoid 324 arthritis, is a recombinant, slightly modified version of the IL1RN protein examined in our study 325 that binds to IL1R1, blocking its actions (Supplementary Fig. 9 ). The observed association 326 between higher levels of IL1RN protein and lower odds of gout are consistent with the beneficial 327 effect of its synthetic analogue anakinra on other inflammatory diseases and suggest a 328 repurposing opportunity for anakinra to treat acute gout flares. In fact, such evaluations are 329 ongoing, with a recent randomized, double-blind, placebo-controlled trial of acute gout flares 330 showing anakinra to be non-inferior to usual treatment 55 . While drug delivery to plasma proteins 331 and their cell surface receptors is easier than to other molecules such as intra-nuclear proteins, 332 druggabilty of any implicated protein in our study depends on various factors such as protein 333 structure and biological functions, and needs to be evaluated on a case-by-case basis. A 334 systematic connection of all cis-heritable proteins to active drug candidates is provided as an 335 additional resource (Supplementary Table 18 We present a comprehensive analysis of cis-genetic regulation of the plasma proteome based on 340 a large discovery study that include both EA and AA individuals and an additional replication study 341 based on AA individuals. Our study almost tripled the number of genes with identified cis-pQTL 342 compared to previous reports 16, 17 and led to, for the first time, understanding of unique genetic 343 architecture of plasma proteome in the AA population. We developed models for plasma protein 344 imputation separately for EA and AA populations and make them publicly available to facilitate future proteome wide association studies. Using large-scale GWAS summary-statistics from two 346 complex traits, we illustrate how PWAS can complement TWAS for the identification of causal 347 genes, protein products and inform potential drug targets. We have created a web resource for 348 downloading summary-statistics data and PWAS models with searchable options for 349 exploring/viewing various results from our analyses (http://nilanjanchatterjeelab.org/pwas). 350 Our analysis provides several important insights into the cis-genetic architecture of plasma 352 proteome. We observe that cis-heritability of protein levels tends to be smaller compared to 353 those of gene expression levels in related tissues (Fig. 3a) , a pattern consistent with the central 354 dogma of DNA regulating the proteome through the transcriptome and the widespread presence 355 of post-translational modification. Further, while cis-heritability of plasma proteome is fairly 356 comparable across EA and AA populations, we observe important heterogeneity. We found 357 nearly 30% of the sentinel pQTLs detected in the AA population were non-existent or extremely 358 rare in the EA population, but the converse proportion was much more modest (~10%). We 359 further observe that the predictive performance of protein imputation model for the AA 360 population, in spite of its much smaller sample size, is comparable to that for the EA population 361 (Fig. 3b) , and cross-population performance of such model is better from AA to EA population 362 than the converse (Fig. 3c) . Further, fine-mapping analysis using SuSiE indicated that the size of 363 "credible set" for many genes is substantially smaller in the AA than the EA population. Taken all 364 together, our analysis demonstrates that similar to what has been reported earlier for more We demonstrate applications of protein imputation models for conducting proteome-wide 380 association studies (PWAS) for two related complex traits, resulting in the exemplary 381 identification of the IL1RN protein which indicates potential promise for drug repurposing of 382 anakinra to treat acute gout flares. Through multivariate analysis, we further explored 383 relationship between plasma PWAS signals and those detected at the transcriptome level 384 through complementary TWAS approach across various tissues. We found that while TWAS 385 signals often exist in the same region, the underlying genes for which the strongest signals are 386 seen can differ or/and the underlying tissue may not be closely related to plasma. As plasma 387 proteins are easier target for drug delivery, we created an additional resource connecting all 388 cis-heritable proteins to active drug candidates (Supplementary Table 18 ). In general, we 389 believe the most promising target genes could be where there exists both PWAS and TWAS 390 signals with underlying evidence of genetic correlation and colocalization. 391 392 Our study has several limitations. First, while the platform we used included SOMAmers for close 393 to 5,000 proteins or protein complexes, it does not provide coverage for the entire plasma 394 proteome. In the future, more comprehensive protein measurements across different tissues will 395 be needed to further pinpoint target genes and tissues of actions. Second, the power of our PWAS 396 analysis conditional on TWAS signals may be affected by small sample size of underlying eQTL 397 datasets. Third, in this study, we have not carried out a joint analysis of the data across the two 398 population and thus may have incurred some loss of power for the identification of shared pQTLs. 399 Fourth, we have not explored effects of uncommon and rare variants, as well as complex trans-400 associations, all of which could have significant impact in explaining heritability, but substantial 401 discovery is likely to need even larger sample size. Plasma protein data availability: Pre-existing data access policies for each of the parent cohort 457 studies (ARIC and AASK) specify that research data requests can be submitted to each steering 458 committee; these will be promptly reviewed for confidentiality or intellectual property 459 restrictions and will not unreasonably be refused. Please refer to the data sharing policies of 460 these studies. Individual level patient or protein data may further be restricted by consent, 461 confidentiality or privacy laws/considerations. These policies apply to both clinical and 462 proteomic data. to plasma proteins or protein complexes encoded by autosomal genes, we further excluded 158 genes on the X chromosome, and 2 genes on the Y chromosome. In total, 4,657 SOMAmers 493 measuring 4,483 unique proteins or protein complexes encoded by 4,435 autosomal genes 494 passed quality control, and were retained in the current study. 495 Genotyping of ARIC samples was performed on the Affymetrix 6.0 DNA microarray and 496 imputed to the TOPMed reference panel (Freeze 5b) 58, 59 . The SNPs with imputation quality R 2 < 497 0.8, call rates <90%, Hardy-Weinberg equilibrium p-values < 10 -6 , or minor allele frequencies <1% 498 were excluded. Genetic principal components show that the two self-reported ethnic subgroups, 499 European Americans (EA) and African Americans (AA) are well distinguished in terms of genetic 500 ancestry (Supplementary Fig. 10 ) 60 . 501 502 Plasma protein data processing. Additional variation in high-throughput gene expression data 503 which is not due to genetic variants has been found to impact the power of eQTL discoveries 8, 9 . 504 The fluctuations of internal environment, experimental deviations, and batch effects can all have 505 large influence on high throughput measurements 33 . To study whether this type of variance 506 exists in our high-throughput plasma protein data measured by the SOMAmers, we performed 507 analysis of variance (ANOVA) test for non-genetic factors to the first 10 principal components 508 (PCs) of log-transformed relative abundance of SOMAmers. Non-genetic factors include common 509 covariates (age, sex, and study sites at v3), as well as batch effects (plate run date, scanner ID, 510 plate position, and subarray). (Supplementary Table 19) . 511 To account for those non-genetic variances, which may obscure genetic association signals, we 512 used the Probabilistic Estimation of Expression Residuals (PEER) method to estimate a set of 513 latent covariates, and put them linearly in the model 34 . The number of PEER factors for each ancestry was selected to maximize the number of significant SOMAmers, i.e. SOMAmers with a 515 significant cis-pQTL near the putative protein's gene. 516 The log-transformed relative abundance of SOMAmers were adjusted in a linear regression 517 model including PEER factors and the covariates sex, age, study site, and 10 genetic principal 518 components (PCs). The residuals from this linear regression were then rank-inverse normalized 519 to avoid the influence of extreme values, and were used as the corrected-protein quantification 520 in the analysis. By analyzing up to 200 PEER factors in increments of 10, the maximum of number 521 of significant SOMAmers were achieved at 90 and 80 PEER factors for EA and AA respectively (Fig. 522 1a) . Thus, the corrected-protein quantifications adjusted for 90 and 80 PEER factors were used 523 as phenotypes in the analysis of the EA and AA populations, respectively. 524 525 Significant SOMAmers discovery. Significant SOMAmer is defined as SOMAmer with a significant 526 cis-pQTL near the putative protein's gene. For all primary analyses, we defined the mapping 527 window as 500-kb upstream and downstream of the target protein-coding genes' transcription 528 start site (TSS). In a secondary analysis, we found that cis-heritability of SNPs within +/-500Kb 529 and +/-1Mb of the TSS to be quite similar, indicating that vast majority of cis-pQTLs for the larger 530 region to be concentrated within +/-500Kb window (Supplementary Table 20) . Gene position of 531 GRCh38 reference genome was obtained from Ensembl BioMart database 57 . Common linear 532 regression procedures for association tests using the Bonferroni correction to p-values usually 533 proves to be overly stringent and results in many false negatives 38 . To overcome this issue, 534 adaptive permutation approach implemented in QTLtools were applied 37 . We used one hundred 535 permutations to empirically characterize the null distribution of the strongest signal which is 536 fitted by a Beta distribution. The p-values of association adjusted for the number of variants tested in cis given by the fitted beta distribution were used to calculate gene-level q-values. By 538 controlling the false discovery rate (FDR) threshold < 5%, significant SOMAmers were identified. 539 cis-SNPs which have independent effects. To identify independent signals for them, we 567 performed independent cis-pQTL mapping using the conditional pass implemented in QTLtools 568 37 .The algorithm first uses permutations to derive a nominal p-value per SOMAmer, then it uses 569 a forward-backward stepwise regression to select the conditional independent signals. In this 570 process, it automatically learns the number of independent signals per SOMAmer using forward 571 selection, and then determines the best candidate SNP per signal using backward selection 572 controlling for the remaining signals. If no SNP is significant at the previous nominal p-value 573 threshold, the candidate signal will be dropped; otherwise, the SNP with smallest backward-p-574 value will be chosen as the lead SNP for this candidate signal. In some cases, the same SNP during 575 the backward selection can explain multiple independent signals that were detected during the 576 forward selection. In the reporting our results (Supplementary Table 6 .1 and 6.2), we show the 577 rank of all the SNPs selected by the forward selection step that is explained by a given lead SNP 578 selected during the final backward selection step. 579 To account for power for detection in Fig. 1c , we adjusted the SNP effect sizes by assigning a 580 weight of the inverse of statistical power. The statistical power can be derived as following. 581 The SNP effect is chi-square distributed with one degree of freedom (df). It is a central chi-582 square distribution under the null, and a non-central chi-square distribution under the alternative 583 hypothesis. The non-centrality parameter (NCP), , is cis-pQTLs by altering binding affinity, instead of protein abundance. Following a procedure 595 recommend earlier 16 , we cataloged all cis-pQTLs that were not in LD (r 2 <0.1) with any PAV in 596 the cis region or those in LD (0.1≤r 2 ≤0.9) but remain significant in a conditional analysis after 597 adjusting for PAVs. We annotated variants with variant effect predictor (VEP) 39 , Loss-Of-598 Function Transcript Effect Estimator (LOFTEE) 40 and Ensembl Regulatory Build 41 . Variants were 599 considered to be PAV if annotated as coding sequence, frameshift, in-frame deletion, in-frame 600 insertion, missense, splice acceptor, splice donor, splice region, start lost, stop gained, or stop 601 lost variants. LD-pruned (r 2 >0.9) PAVs were included as covariates for association testing. 602 603 Cis-eQTL overlap. We cross referenced the identified cis-pQTLs against cis-eQTLs identified in the 604 overall analysis of GTEx (V8) data across different tissues. For each SOMAmer, we first extracted 605 the sentinel cis-pQTLs, meaning the variants having most significant association for a pGene along 606 with all the variants in high LD (r 2 > 0.8). Using this list of variants across 2,004 SOMAmers which 607 had at least one cis-pQTL in EA, we calculated the percentage overlap with the set of significant 608 cis-eQTLs (at FDR<5%, as defined by GTEx consortium) for the same gene identified in each tissue 609 of GTEx V8 9 . Since the GTEx cohort is primarily of European ancestry, we restricted this analysis 610 to EA only. 611 612 Colocalization. Colocalization analysis was performed to investigate whether the same variants 613 were likely to be causal for variation in protein levels and gene expression levels. We used 614 publicly available overall cis-eQTL summary statistics from GTEx consortium (V8). For testing 615 whether cis-eQTL and cis-pQTL associations for the same gene colocalize, we used coloc package 616 in R with the default setting 63 . Evidence for colocalization was assessed using the posterior 617 probability (PP) for the hypothesis that there is an association for both protein levels and gene 618 expression levels, and they are driven by the same causal variant (PP.H4). Since we tested across 619 a large number of tissues, we chose a stringent cut-off of 0.8 and pGenes with PP.H4 > 0.8 were 620 identified as likely to have a shared causal variant for the cis-eQTL and cis-pQTL associations. As 621 before, we restricted our analysis to the 2,004 pGenes identified in EA. The NHGRI-EBI GWAS Catalog of published genome-wide association 769 studies, targeted arrays and summary statistics 2019 10 years of GWAS discovery: biology, function, and translation. The 772 Non-coding genetic variants in human disease Making sense of GWAS: using epigenomics and genome 776 engineering to understand the functional relevance of SNPs in non-coding regions of the human 777 genome From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol 779 locus Human disease-associated genetic variation impacts large intergenic non-781 coding RNA expression The genotype-tissue expression (GTEx) project Genetic effects on gene expression across human tissues The GTEx Consortium atlas of genetic regulatory effects across human 787 tissues Cross-tissue and tissue-specific eQTLs: partitioning the heritability of a 789 complex trait Leveraging molecular quantitative trait loci to understand the genetic 791 architecture of diseases and complex traits Aptamer-based multiplexed proteomic technology for biomarker discovery Plasma protein patterns as comprehensive indicators of health The human plasma proteome: history, character, and 797 diagnostic prospects Genomic and drug target evaluation of 90 cardiovascular proteins in 799 30,931 individuals Genomic atlas of the human plasma proteome Human serum proteome profoundly overlaps with genetic signatures of 802 disease Genome-wide mapping of plasma protein QTLs identifies putatively causal 804 genes and pathways for cardiovascular disease Genetic architecture of host proteins involved in SARS-CoV-2 infection A Neanderthal OAS1 isoform protects individuals of European ancestry 808 against COVID-19 susceptibility and severity Genomic and multi-tissue proteomic integration for understanding the 810 biology of disease and other complex traits Genome-wide pQTL analysis of protein 812 expression regulatory networks in the human liver Integrating human brain proteomes with genome-wide association data 814 implicates new proteins in Alzheimer's disease pathogenesis Linking protein to phenotype with Mendelian Randomization detects 816 38 proteins with causal roles in human diseases and traits Connecting genetic risk to disease end points through the human blood 818 plasma proteome Phenome-wide Mendelian randomization mapping the influence of the 820 plasma proteome on complex diseases A gene-based association method for mapping traits using reference 822 transcriptome data Integrative approaches for large-scale transcriptome-wide association 824 studies The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC 826 investigators Cross-platform proteomics to advance genetic prioritisation strategies Evaluating the potential role of pleiotropy in 830 Mendelian randomization studies Target genes, variants, tissues and transcriptional pathways influencing human 832 serum urate levels A Bayesian framework to account for complex non-834 genetic factors in gene expression levels greatly increases power in eQTL studies Using probabilistic estimation of 837 expression residuals (PEER) to obtain increased power and interpretability of gene expression 838 analyses Design and statistical aspects of the African American Study of Kidney 840 Disease and Hypertension (AASK) Distribution of allele frequencies and effect sizes and their interrelationships 843 for common genetic susceptibility variants A complete tool set for molecular QTL discovery and analysis Fast and efficient QTL 848 mapper for thousands of molecular phenotypes The ensembl variant effect predictor The mutational constraint spectrum quantified from variation in 851 141,456 humans The ensembl 853 regulatory build A simple new approach to variable 855 selection in regression, with application to genetic fine mapping Transethnic meta-analysis of genomewide association studies Structural determinants of human ζ-globin 860 mRNA stability Effect of ζ-globin substitution on the O2-transport properties of Hb S in 862 vitro and in vivo A Multicenter Trial of the Effectiveness of ζ-Globin Enzyme-Linked 864 Immunosorbent Assay and Hemoglobin H Inclusion Body Screening for the Detection of α0-865 Thalassemia Trait A global view of the genetic 867 architecture in human complex traits The allelic landscape of human blood cell trait variation and links to 870 common complex disease GCTA: a tool for genome-wide complex 872 trait analysis Opportunities and challenges for transcriptome-wide association 874 studies Genomes Project Consortium. A global reference for human genetic variation A comparison of selected mRNA and protein abundances in 878 human liver Integrating gene expression with summary association statistics to 880 identify genes associated with 30 complex traits Genome-wide association analyses identify 18 new loci associated with 883 serum urate concentrations Anakinra for the treatment of acute gout flares: a randomized, double-885 blind, placebo-controlled, active-comparator, non-inferiority trial Genetic analyses of diverse populations improves discovery for complex 888 traits BioMart and Bioconductor: a powerful link between biological databases 890 and microarray data analysis Use of> 100,000 NHLBI Trans-Omics for Precision Medicine (TOPMed) 892 Consortium whole genome sequences improves imputation quality and detection of rare 893 variant associations in admixed African and Hispanic/Latino populations A flexible and accurate genotype imputation 896 method for the next generation of genome-wide association studies Principal components analysis corrects for stratification in genome-wide 899 association studies Statistical power in genome-wide association studies and quantitative 901 trait locus mapping Genetic components of human pain sensitivity: a protocol for a genome-903 wide association study of experimental pain in healthy volunteers Bayesian test for colocalisation between pairs of genetic 905 association studies using summary statistics Molecular QTL discovery incorporating genomic annotations using Bayesian false 907 discovery rate control From genome-wide associations to candidate causal 909 variants by statistical fine-mapping Trans-ethnic fine mapping highlights kidney-function genes linked to salt 911 sensitivity The UK Biobank resource with deep phenotyping and genomic data Exploring the phenotypic consequences of tissue specific gene 915 expression variation inferred from GWAS summary statistics Therapeutic target database 2020: enriched resource for facilitating research 918 and early development of targeted therapeutics The druggable genome and support for target identification and validation in 920 drug development The UCSC Genome Browser database: 2021 update. Nucleic Acids 922 Res Conditional and joint multiple-SNP analysis of GWAS summary statistics 924 identifies additional variants influencing complex traits to the GCTA to estimate cis-h 2 using the REML algorithm (option --reml --reml-no-constrain). A 660 maximum number of 100 iterations was set to determine the convergence of the estimation 661 algorithm. The nonzero cis-heritability was tested using a likelihood-ratio test for the first genetic 662 variance component (option --reml-lrt 1) with significance level of 0.01. Plasma protein 663SOMAmers with negative estimate cis-h 2 estimates were excluded. Cis window size of +/-500Kb 664 and 1Mb were examined, and there were no significant differences between the heritability 665 estimations ( Supplementary Table 20) . Therefore, throughout the paper, we defined +/-500Kb 666 window size which is same as those used for TWAS models we used. 667 668 Imputation models trained jointly with cis-SNPs. Using the TWAS / FUSION software 28 , we built 669 imputation models for 1,394 (AA) and 1,350 (EA) SOMAmers with significant non-zero cis-h 2 . 670 Imputation model for a SOMAmer was trained jointly by elastic net using cis-SNPs in +/-500Kb 671 around the TSS of the encoding gene of the target protein. The performance of models was 672 evaluated by adjusted prediction accuracy which was defined as the 5-fold cross-validated R 2 673 between predicted and true values standardized by cis-h 2 . The imputation models built only with 674 the top cis-pQTL was used as a baseline comparison. 675 676 Trans-ethnic prediction capacity. To study the trans-ethnic prediction performance, we applied 677 the genetic imputation models to the genotypes of individuals from their opposite races in ARIC. 678The cross-ethnic prediction performance is evaluated by the R 2 between predicted and true 679 values standardized by cis-h 2 . Here we only studied for genes significant cis-heritable (p-value of cis-h 2 from GCTA < 0.01) for 691 both gene expression levels and plasma protein levels ( Supplementary Tables 15.1 Since the gene expression imputation models were derived using participants predominantly 693 from European ancestry from GTEx V7, the plasma protein imputation models here were 694 restricted to EA-derived only. If multiple transcripts or SOMAmers were measured for the same 695 gene, the sum of their imputed levels was used to represent "the total level of the gene" in terms 696 of gene expression or plasma protein level. We also obtained preliminary gene-expression 697 imputation models trained based on GTEx V8 dataset (obtained based personal communication 698 with Gusev lab) and used them to conduct several secondary/validation analyses for comparison 699 of results with V7. 700 701 Proteome-wide association studies (PWAS). As an analog of TWAS, weights in the imputation 702 models of SOMAmers can be applied to summary level data using the test statistics derived in 703 TWAS / FUSION. The mathematical derivation can be found in the original paper 28 . The type 1 704 error of PWAS is well-controlled in simulation using null phenotypes simulated from UK Biobank 705 using 337,484 unrelated European ancestry individuals 67 . Note that the enet model coefficients 706 for 9 proteins in AA and 2 proteins in EA were all zero. These proteins were excluded in PWAS 707 analysis, and therefore, 1,385 (AA) and 1,348 (EA) imputation models were available in PWAS. 708The significance level for PWAS loci identification is adjusted by of the total number of imputation 709 models for significant cis-heritable plasma proteins or protein complexes (p-value < 710 0.05/1,348=3.7x10 -5 in EA which was used in our PWAS of serum urate and gout). As discussed in 711 a recent TWAS paper 50 , multiple SOMAmers, whose encoding genes of their target proteins or 712 protein complexes locate closely in a locus, were sometimes identified at the same time. To 713 identify distinct loci, a 1Mb region (+/-500Kb of TSS) was defined around each encoding gene of 714 the target protein of significant SOMAmers, and overlapping regions were merged. The sentinel 715 association in each locus was selected to be the top PWAS candidate hit for this region 716 (Supplementary Tables 21.1 and 21.2) . 717We obtained standardized estimate for the causal effect (̂) and standard error ( (̂)), and 718 thereby confidence intervals, of the underlying proteins on the complex traits ( ) by slightly 719 extending S-PrediXcan 68 . We derived these as 720 all TWAS genes nearby (+/-500Kb around) whose TSS locate within 500Kb of the TSS of its sentinel 735 PWAS gene, and selected the one with the smallest TWAS p-value. The position of genes in TWAS 736 (based on GTEx V7 based on genome build GRCh37) and PWAS (based on genome build GRCh38) 737 were matched using the UCSC genome browser webtool (https://genome.ucsc.edu/cgi-738 bin/hgLiftOver) 71 . 739We first performed the nearby TWAS in two trait-relevant tissues, whole blood and liver, for 740 serum urate and gout. Note that kidney is also a trait-relevant tissue, but there is no imputation 741 model trained with GTEx V7 data available on TWAS / FUSION for kidney. The significance of the 742 nearby TWAS hit was determined by significance level after Bonferroni Correction ( 0.05/ 743 ∑ #transcripts with imputation models ). 744 Similarly, the conditional z-score of the nearby TWAS gene is 757We then performed the same procedure for all nearby TWAS genes in all GTEx V7 tissues. Using 760Bonferroni Correction for the total number of transcripts with imputation models ( 0.05/ 761 ∑ #transcripts with imputation models ), we identified the tissues which have at 762 least one significant TWAS gene in the PWAS significant loci. The most significant TWAS gene in 763 this region and its corresponding tissue were recorded, and then used to perform conditional 764 analysis (Supplementary Tables 22.1 and 22.2) . We further validated the top gene-tissue 765 combination identified through TWAS models in V7 using preliminary models that were available 766 to us based on V8. 767 *Genes and tissues that are significant in TWAS after Bonferroni correction of all GTEx V7 transcripts across all tissues (p-value < 0.05 / 37,366 = 1.34x10 -6 ). 981 **A tissue is defined significant if there is at least one transcript near the PWAS signal for which the TWAS is significant at p-value < 1.34x10 -6 . 982 ***NAs in the table means no applicable TWAS model for transcripts in the defined region 983 B: Gout